LUNG FUNCTION

 
 
 

BREO—The only ICS/LABA
that
provides 24-hour
efficacy
without

a second daily-dose

 

Lasting lung function improvement for a full 24 hours,
starting in 15 minutes*

*Median time to onset (100-mL increase from baseline in mean FEV1) was 15 minutes after beginning treatment

 

In a 12-week study in patients who were symptomatic on a mid- to high-dose ICS

BREO 100/25 (n=312) provided a statistically significant 108 mL (30%) improvement in least squares mean change from baseline in wm FEV1 (0-24 hours) compared with FF (fluticasone furoate) 100 mcg (n=288) (P<0.001) at Week 12."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1
 
  • wm FEV1: in a subset of patients, BREO 100/25 (n=108) demonstrated a numerically greater improvement in change from baseline in wm FEV1 (0-24 hours) compared with FF 100 mcg (n=106) of 116 mL (95% Cl: -5, 236; P=0.06) and a statistically significant 302-mL improvement (P<0.001) compared with placebo (n=95) at Week 12
  • Trough FEV1: there was a numerically greater change from baseline in trough FEV1 for BREO 100/25 (n=200) compared with FF 100 mcg (n=203) of 36 mL (95% Cl: -48, 120; P=0.405) and a statistically significant 172-mL improvement (P<0.001) compared with placebo (n=193) at Week 12
FEV1=forced expiratory volume in 1 second; ICS=inhaled corticosteroid.
 
Study Designs
 
More lung function data Adverse Reactions
 
 

24-hour BREO change from baseline in trough FEV1 at Week 12

Change from baseline in trough FEV1 at Week 12"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1
Treatment n Difference from
FF 100 mcg (n=336)
BREO 100/25 334 77 mL (P=0.014)
 
Study Design
 
Go to BREO 200/25
 
 

Lasting lung function improvement for a full 24 hours,
starting in 15 minutes*

*Median time to onset (100-mL increase from baseline in mean FEV1) was 15 minutes after beginning treatment.

 

In a 24-week study in patients who were symptomatic on a mid- to high-dose ICS

In a subset of patients, BREO 200/25 (n=89) provided a statistically significant 136 mL (41%) improvement in least squares change from baseline in wm FEV1 (0-24 hours) compared with FF (fluticasone furoate) 200 mcg (n=83) (P=0.048) at Week 24."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"5
 
FEV1=forced expiratory volume in 1 second; ICS=inhaled corticosteroid.
 
Study Design
 
Go to BREO 100/25 Adverse Reactions
 

24-hour BREO change from baseline in trough FEV1 at Week 24

Change from baseline in trough FEV1 at Week 24"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"5
Treatment n Difference from
FF 200 mcg (n=186)
BREO 200/25 187 193 mL (P<0.001)
 
Study Design
 
Go to BREO 100/25
 
 

Looking for samples?
Looking for a savings offer?
Subject to eligibility. Restrictions apply.

 

Chat